Year 2024 / Volume 116 / Number 4
Letter
Transient second-degree type 2 atrioventricular block after infliximab infusion in a patient with Crohn’s disease and heterozygous familial hypercholesterolemia

233-234

DOI: 10.17235/reed.2023.9950/2023

Youyan Jin, Wei Wei, Cong Hou, Zehong Liang, Jiali Wang, Huang Zhong,

Abstract
Current treatments for patients in the active phase of Crohn's disease (CD) include conventional treatments and biological treatments. Infliximab (IFX), a TNF-α antagonist, is recommended to induce remission in patients with moderate-to-severe CD who have not responded to conventional therapy. IFX terminates the inflammatory cascade by inhibiting the nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and caspase signaling pathways and increases the apoptosis of activated T cells in inflamed tissues.
Share Button
New comment
Comments
No comments for this article
References
1. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2020;14:4-22.
2. Zubielienė K, Valterytė G, Jonaitienė N, et al. Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis. Medicina (Kaunas) 2022;58.
3. Singh S, Bittner V. Familial hypercholesterolemia--epidemiology, diagnosis, and screening. Curr Atheroscler Rep 2015;17:482.
Related articles

Letter

Isolated Jejunal Crohn's Disease: a challenging diagnosis

DOI: 10.17235/reed.2022.9423/2022

Letter

Comb sign in Crohn’s disease

DOI: 10.17235/reed.2022.9132/2022

Letter

Ectopic ACTH syndrome in a patient with Crohn’s disease

DOI: 10.17235/reed.2022.8825/2022

Letter

Pulmonary nodules in a patient with Crohn’s disease

DOI: 10.17235/reed.2022.8499/2021

Letter

Adenocarcinoma of the small intestine in Crohn's disease

DOI: 10.17235/reed.2021.8050/2021

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Citation tools
Jin Y, Wei W, Hou C, Liang Z, Wang J, Zhong H, et all. Transient second-degree type 2 atrioventricular block after infliximab infusion in a patient with Crohn’s disease and heterozygous familial hypercholesterolemia. 9950/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1034 visits.
This article has been downloaded 27 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 11/09/2023

Accepted: 14/09/2023

Online First: 29/09/2023

Published: 09/04/2024

Article Online First time: 18 days

Article editing time: 211 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology